OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ: TBIO) today announced that it has established a Clinical-Commercial Advisory Board (CCAB) for oncology applications of its Multiplexed ICE ...

Current Status, Existing and Future Applications of COLD-PCR for Cancer and Prenatal Diagnosis to Be Presented NEW HAVEN, Conn., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company ...

Trials underway at five laboratories and two diagnostic equipment companies NEW HAVEN, Conn., June 19, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today ...

1 Division of DNA Repair and Genome Stability, Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA 2 2Division of Medical Physics ...

Association of Notch-1 phenotype with clinical stage progression in non-small cell lung cancer. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not include a ...

Cold-PCR was invented at Dana-Farber by Dr. Mike Makrigiorgos who has demonstrated its effectiveness in enriching for mutations in cancer-related genes in samples where DNA sequencing cannot detect ...

OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCQB: TBIO) today reported that the European Patent Office (EPO) has confirmed its intention to grant a patent covering multiplexed ICE COLD-PCR ...

To assess COLD-PCR enrichment, many different assays can be applied, either in combination with COLD-PCR (real-time COLD-PCR [35]) or downstream, in order to analyze enriched genetic variations. The ...

OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (TBIO) (NASDAQ: TBIO), today announced a licensing agreement with leading Canadian laboratory services provider LifeLabs, which has selected ...

Since its original development (2008) COLD-PCR has been used by several groups for increasing the sensitivity of mutation detection in different settings including cancer diagnostics and prenatal ...

The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not ...